BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bookstaver PB, Jenkins TC, Stenehjem E, Doron S, Brown J, Goldwater SH, Lopes C, Haynes A, Udeze C, Mo Y, Gillard P, Liu Y, Keyloun K. Impact of Outpatient vs Inpatient ABSSSI Treatment on Outcomes: A Retrospective Observational Analysis of Medical Charts Across US Emergency Departments. Open Forum Infect Dis 2018;5:ofy109. [PMID: 30581883 DOI: 10.1093/ofid/ofy109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Shealy SC, Alexander C, Hardison TG, Magagnoli J, Justo JA, Derrick C, Kohn J, Winders HR, Privette T, Al-Hasan MN, Bookstaver PB. Pharmacist-Driven Culture and Sexually Transmitted Infection Testing Follow-Up Program in the Emergency Department. Pharmacy (Basel) 2020;8:E72. [PMID: 32340149 DOI: 10.3390/pharmacy8020072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gonzalez J, Andrade DC, Niu J. Cost-consequence analysis of single-dose dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections in a multi-site healthcare system. Clin Infect Dis 2020:ciaa1732. [PMID: 33211794 DOI: 10.1093/cid/ciaa1732] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Bookstaver PB, Milgrom A. Stewarding the costly antibiotic: considerations for dalbavancin. Clin Infect Dis 2020:ciaa1730. [PMID: 33211844 DOI: 10.1093/cid/ciaa1730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Baxa J, McCreary E, Schulz L, Pulia M. Finding the niche: An interprofessional approach to defining oritavancin use criteria in the emergency department. Am J Emerg Med 2020;38:321-4. [PMID: 31839519 DOI: 10.1016/j.ajem.2019.158442] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]